SQI Diagnostics’ testing partner, KSL Diagnostics, has received conditional approval from the New York State Department of Health (NYSDOH) for the EXACT COVID-19 Antibody Test.

The advanced Covid-19 antibody test is designed for the semi-quantitative measurement of six distinct antibodies, which are produced by the immune system in response to the SARS CoV-2 virus.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test will be conducted using a small volume blood sample collected in a home or office setting.

SQI Diagnostics stated that a positive test result might indicate the presence of antibodies arising from a previous Covid-19 infection or vaccination.

The company also said that its EXACT COVID-19 Antibody Test will now be available to physicians and patients in the US through telemedicine testing company AZOVA.

SQI Diagnostics CEO Andrew Morris said: “The EXACT COVID-19 Antibody Test is the next generation of tools in the fight against Covid-19. It gives peace of mind because it can detect an immune response in both vaccinated and previously Covid-19 infected people. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It also has the potential to give the health care system key insights and data into the relationship between antibody levels and breakthrough infections and reinfections.

“We’re bringing these tests to market now because we are determined to do our part to end the pandemic.”

Last month, the company completed the acquisition of Precision Biomonitoring’s human diagnostic Covid-19 PCR testing business as well as its TripleLock molecular diagnostic testing technology.

In 2019, SQI Diagnostics and University Health Network (UHN) tested new technology to help surgeons evaluate lung health during transplantation.